Literature DB >> 31886456

Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria.

Djamilia Dierov1, Nicholas Webb1, Samira Fatmi1, Chamberlain Nwanne2, Cristi Ciolino1, Kara Mosesso1, Jimmy Nieves1, Miguel-Angel Perales1,3, Susan E Prockop4, Doris M Ponce1,3.   

Abstract

GVHD is a frequent complication following allo-HCT. The NIH consensus group established new guidelines for the evaluation of chronic GVHD. However, GVHD assessment remains challenging due its complexity and requirement for laborious evaluation. We, therefore, established a standardized approach for the assessment of chronic GVHD in accordance with the NCC guidelines. At a single institution, all allograft recipients were evaluated for GVHD within the first-year post allo-HCT following a 3-step workflow (real-time assessment, consensus review, and documentation). A GVHD adjudication committee was created and a dynamic electronic GVHD data capture form was developed guiding the clinician through a comprehensive review of systems following the NCC guidelines. We found that the assessment and reporting of GVHD reached 100% compliance. The establishment of an institutional GVHD adjudication committee enabled standardized assessment of GVHD. Our workflow can be adopted by other centers to create a similar framework for dedicated GVHD evaluation.

Entities:  

Keywords:  GVHD; data management; quality improvement

Year:  2019        PMID: 31886456      PMCID: PMC6934358          DOI: 10.1002/acg2.62

Source DB:  PubMed          Journal:  Adv Cell Gene Ther        ISSN: 2573-8461


  43 in total

1.  Evaluation of prognostic factors among patients with chronic graft-versus-host disease.

Authors:  Jose A Pérez-Simón; Gabriel Afram; Rodrigo Martino; Jose L Piñana; Teresa Caballero-Velazquez; Olle Ringden; David Valcarcel; Dolores Caballero; Mats Remberger; Yanira de Paz; Jordi Sierra; Jesús San Miguel; Hans Hagglund
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

2.  Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.

Authors:  Joon Ho Moon; Sang Kyun Sohn; Anna Lambie; Laura Ellis; Nada Hamad; Jieun Uhm; Vikas Gupta; Jeffrey H Lipton; Hans A Messner; John Kuruvilla; Dennis Kim
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-18       Impact factor: 5.742

3.  Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study.

Authors:  Joseph Pidala; Georgia Vogelsang; Paul Martin; Xiaoyu Chai; Barry Storer; Steven Pavletic; Daniel J Weisdorf; Madan Jagasia; Corey Cutler; Jeanne Palmer; David Jacobsohn; Sally Arai; Stephanie J Lee
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

4.  Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.

Authors:  Stephen Harnicar; Doris M Ponce; Patrick Hilden; Junting Zheng; Sean M Devlin; Marissa Lubin; Melissa Pozotrigo; Sherry Mathew; Nelly Adel; Nancy A Kernan; Richard O'Reilly; Susan Prockop; Andromachi Scaradavou; Alan Hanash; Robert Jenq; Marcel van den Brink; Sergio Giralt; Miguel A Perales; James W Young; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2015-02-14       Impact factor: 5.742

5.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

6.  Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.

Authors:  Pere Barba; Patrick Hilden; Sean M Devlin; Molly Maloy; Djamilia Dierov; Jimmy Nieves; Matthew D Garrett; Julie Sogani; Christina Cho; Juliet N Barker; Nancy A Kernan; Hugo Castro-Malaspina; Ann A Jakubowski; Guenther Koehne; Esperanza B Papadopoulos; Susan Prockop; Craig Sauter; Roni Tamari; Marcel R M van den Brink; Scott T Avecilla; Richard Meagher; Richard J O'Reilly; Jenna D Goldberg; James W Young; Sergio Giralt; Miguel-Angel Perales; Doris M Ponce
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-23       Impact factor: 5.742

7.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.

Authors:  John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

8.  Mycophenolate mofetil-induced colitis in children.

Authors:  Uma Padhye Phatak; Patricia Seo-Mayer; Dhanpat Jain; Megan Selbst; Sohail Husain; Dinesh S Pashankar
Journal:  J Clin Gastroenterol       Date:  2009 Nov-Dec       Impact factor: 3.062

9.  Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Aazim K Omer; Daniel J Weisdorf; Aleksandr Lazaryan; Ryan Shanley; Bruce R Blazar; Margaret L MacMillan; Claudio Brunstein; Nelli Bejanyan; Mukta Arora
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-29       Impact factor: 5.742

10.  EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.

Authors:  Helene M Schoemans; Stephanie J Lee; James L Ferrara; Daniel Wolff; John E Levine; Kirk R Schultz; Bronwen E Shaw; Mary E Flowers; Tapani Ruutu; Hildegard Greinix; Ernst Holler; Grzegorz Basak; Rafael F Duarte; Steven Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2018-06-05       Impact factor: 5.483

View more
  2 in total

1.  Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.

Authors:  Natasia Rodriguez; Jasme Lee; Lisa Flynn; Fiona Murray; Sean M Devlin; Cristina Soto; Christina Cho; Parastoo Dahi; Sergio Giralt; Miguel-Angel Perales; Craig Sauter; Doris M Ponce
Journal:  Transplant Cell Ther       Date:  2021-05-21

2.  Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study.

Authors:  Ran Reshef; Wael Saber; Javier Bolaños-Meade; George Chen; Yi-Bin Chen; Vincent T Ho; Doris M Ponce; Ryotaro Nakamura; Michael J Martens; John A Hansen; John E Levine
Journal:  J Clin Oncol       Date:  2021-01-28       Impact factor: 50.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.